Currax Launches Campaign Focused on Food Noise and its Impact on Weight Loss

Stock.adobe.com

Over the past two years, there’s been a renewed focus in the pharmaceutical industry on weight loss medication. This is thanks to the success of Wegovy and Ozempic, too popular GLP-1s that are regularly used by people looking to manage their weight. However, it’s also important to remember that even with the assistance of medication, the only way to reduce body fat percentage is by eating fewer calories than are being consumed.

For many people, this continues to be a struggle.

Currax Pharmaceuticals, a pharmaceutical company focused on producing anti-obesity treatments, announced a new campaign centered on the topic of food noise.¹ This is a term used to describe constant and intrusive thoughts about food while attempting to lose weight. The campaign, named Quiet the Food Noise, hopes to raise awareness and make people more comfortable with discussing these issues with their healthcare providers.

In a press release, My Weight - What to Know founder Ansley Dalbo said, “We've heard from so many people living with obesity that dealing with constant ‘food noise’ is a significant challenge for them in everyday life. These persistent thoughts about food can impact mental health and can also make weight management more difficult. Recognizing this is a critical first step in combatting weight bias (both internal and external) and de-stigmatizing the choice to seek medical help for obesity."

Currax produces a variety of anti-obesity treatments, including Contrave/Mysimba. In August, the company announced the results of a study that researched the possibility of the drug causing excess cardiovascular risk.²

In a press release, Currax Pharmaceuticals chief medical officer and SVP Michael Kyle, MD, said, “We are honored to have Dr. Burns present these favorable findings at ISPE. Achieving this milestone and the affirmation of the cardiovascular safety of Contrave is gratifying. Over the past four years, we worked exhaustively with regulatory agencies to fully characterize the cardiovascular safety of the product and these results are another proof-point of the positive benefit-risk of Contrave/Mysimba.”

The study’s presenting author and senior managing scientist at Exponent (who led the analysis) Dustin Burns, PhD, added, “The study’s results found no evidence of increase in cardiovascular risk among initiators of Contrave, which is informative for healthcare providers and patients considering this treatment option for obesity.”

The pharmaceutical industry has also struggled with being able to maintain a proper supply of certain anti-obesity drugs in recent years. In July, Currax announced the development of a new facility in the European Union to ensure a continuity of supply for these medications.³

In a press release issued at the time, Currax Pharmaceuticals president and CEO George Hampton said, “According to the World Health Organization (WHO), one in eight people are living with obesity and we believe those patients deserve consistent access to medications to treat their disease. Access to medications is one of our core values and reliability of supply is a critical component to access. We continue to invest heavily in our ability to supply the unprecedented increase in worldwide demand. This is especially important at a time when the GLP-1 companies are plagued with chronic supply issues."

Sources

1. Currax Pharmaceuticals Unveils New Disease Awareness Campaign to "Quiet the Food Noise," a Key Barrier for Individuals Seeking Weight Loss. Currax Pharmaceuticals. September 24, 2024. https://www.prnewswire.com/news-releases/currax-pharmaceuticals-unveils-new-disease-awareness-campaign-to-quiet-the-food-noise-a-key-barrier-for-individuals-seeking-weight-loss-302257022.html
2. Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study. Currax Pharmaceuticals. August 27, 2024. Accessed September 25, 2024. https://www.curraxpharma.com/press-releases/currax-pharmaceuticals-contrave-mysimba-demonstrates-positive-cardiovascular-safety-in-a-large-real-world-evidence-study/
3. New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues. Currax Pharmaceuticals. July 23, 2024. Accessed September 25, 2024. https://www.curraxpharma.com/press-releases/new-facility-assures-continuity-of-supply-of-anti-obesity-treatment-contrave-mysimba-amidst-glp-1-supply-issues/